Key facts
- This page summarizes Paul Alloway's Form 4 filing for Homology Medicines, Inc. (QTTB).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 27 Mar 2024, 16:15.
Paul Alloway - 25 Mar 2024 Form 4 Insider Report for Homology Medicines, Inc. (QTTB)
- Reporting relationship
- President and Chief Operating Officer
- Issuer ticker
- QTTB
- Reported as of
- 25 Mar 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Mar 2024, 16:15:14 UTC
- Prior SEC filing
- 05 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul Alloway
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Paul Alloway filed Form 4 for Homology Medicines, Inc. (QTTB) on 27 Mar 2024.
Change
- Previous filing in this sequence was filed on 05 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FIXX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +23,530
- Change %
- +84%
- Price
- Shares after
- 51,566
- Date
- 25 Mar 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FIXX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -5,440
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 25 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,440
- Exercise price
- Footnotes
- F1, F2
FIXX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -18,090
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 25 Mar 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,090
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Paul Alloway is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
Footnote F2
The vesting of these RSUs has been accelerated such that the RSUs vested in full on March 25, 2024, immediately prior to the Effective Time as defined in that certain Agreement and Plan of Merger by and among the Issuer, Kenobi Merger Sub, Inc. and Q32 Bio Inc. dated November 16, 2023.
SEC remarks
President and Chief Operating Officer